Giacomo Greco

Pavia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Journal: JAMA neurology

Published: August 17, 2026

Double-Negative Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.

Double-Negative Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: July 17, 2026

The supporting role of Visual Evoked Potentials for the diagnosis of Optic Neuritis within the 2022 ICON criteria.

The supporting role of Visual Evoked Potentials for the diagnosis of Optic Neuritis within the 2022 ICON criteria.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 31, 2026

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Journal: medRxiv : the preprint server for health sciences

Published: February 06, 2026

Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: January 31, 2026

Validation of the MOG-AR Score: A Retrospective Multicenter Study.

Validation of the MOG-AR Score: A Retrospective Multicenter Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: January 28, 2026

Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments.

Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments.

Journal: Journal of neurology

Published: November 03, 2025

Applying the Supporting Features for MOGAD Diagnosis to Patients With Multiple Sclerosis.

Applying the Supporting Features for MOGAD Diagnosis to Patients With Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: October 08, 2025

Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and Discrepancies.

Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and Discrepancies.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 19, 2025

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.

Journal: Brain : a journal of neurology

Published: May 12, 2025

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.

Journal: Brain : a journal of neurology

Published: May 12, 2025

Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study.

Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study.

Journal: CNS drugs

Published: May 06, 2025

Showing 1-12 of 33

Last Updated: 09/26/2026